Advertisement

Drugs & Aging

, Volume 36, Issue 1, pp 39–51 | Cite as

Medical Cannabis for Older Patients

  • Amir Minerbi
  • Winfried Häuser
  • Mary-Ann FitzcharlesEmail author
Review Article

Abstract

Interest in the medicinal use of cannabis and cannabinoids is mounting worldwide. Fueled by enthusiastic media coverage, patients perceive cannabinoids as a natural remedy for many symptoms. Cannabinoid use is of particular interest for older individuals who may experience symptoms such as chronic pain, sleep disturbance, cancer-related symptoms and mood disorders, all of which are often poorly controlled by current drug treatments that may also incur medication-induced side effects. This review provides a summary of the evidence for use of cannabinoids, and medical cannabis in particular, for this age group, with attention to efficacy and harms. Evidence of efficacy for relief of an array of symptoms is overall scanty, and almost all study participants are aged < 60 years. The risk of known and potential adverse effects is considerable, with concerns for cognitive, cardiovascular and gait and stability effects in older adults. Finally, in light of the paucity of clinical evidence and increasing patient requests for information or use, we propose a pragmatic clinical approach to a rational dialogue with older patients, highlighting the importance of individual benefit–risk assessment and shared patient–clinician decision making.

Notes

Author contributions

All authors participated in the writing of this manuscript.

Compliance with Ethical Standards

Conflict of interest

AM and WH have no conflicts of interest. MAF has received consulting fees, speaking fees, and/or honoraria from AbbVie, Amgen, UCB Canada, Palladin Labs, and Pfizer in the last 3 years.

Funding

No sources of funding were used in the preparation of this manuscript.

References

  1. 1.
    D’Souza DC, Ranganathan M. Medical marijuana: is the cart before the horse? JAMA. 2015;313(24):2431–2.Google Scholar
  2. 2.
    Hauser W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management—an overview of systematic reviews. Eur J Pain. 2018;22(3):455–70.Google Scholar
  3. 3.
    Schauer GL, King BA, Bunnell RE, Promoff G, McAfee TA. Toking, vaping, and eating for health or fun: marijuana use patterns in adults, U.S., 2014. Am J Prev Med. 2016;50(1):1–8.Google Scholar
  4. 4.
    Han BH, Palamar JJ. Marijuana use by middle-aged and older adults in the United States, 2015–2016. Drug Alcohol Depend. 2018;1(191):374–81.Google Scholar
  5. 5.
    Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011–20.Google Scholar
  6. 6.
    Leal-Galicia P, Betancourt D, Gonzalez-Gonzalez A, Romo-Parra H. A brief history of marijuana in the western world. Rev Neurol. 2018;67(4):133–40.Google Scholar
  7. 7.
    Friedman D, Sirven JI. Historical perspective on the medical use of cannabis for epilepsy: ancient times to the 1980s. Epilepsy Behav. 2017;70(Pt B):298–301.Google Scholar
  8. 8.
    Haffajee RL, MacCoun RJ, Mello MM. Behind schedule—reconciling federal and state marijuana policy. N Engl J Med. 2018;379(6):501–4.Google Scholar
  9. 9.
    Lucas PG. Regulating compassion: an overview of Canada’s federal medical cannabis policy and practice. Harm Reduct J. 2008;28(5):5.Google Scholar
  10. 10.
    Bogdanoski T. Accommodating the medical use of marijuana: surveying the differing legal approaches in Australia, the United States and Canada. J Law Med. 2010;17(4):508–31.Google Scholar
  11. 11.
    Ablin J, Ste-Marie PA, Schafer M, Hauser W, Fitzcharles MA. Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz (Berlin, Germany). 2016;30(1):3–13.Google Scholar
  12. 12.
    Hazekamp A, Heerdink ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol. 2013;69(8):1575–80.Google Scholar
  13. 13.
    Bicher HI, Mechoulam R. Pharmacological effects of two active constituents of marihuana. Arch Int Pharmacodyn Ther. 1968;172(1):24–31.Google Scholar
  14. 14.
    Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002;68–69:619–31.Google Scholar
  15. 15.
    Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3353–63.Google Scholar
  16. 16.
    Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60(1):255–66.Google Scholar
  17. 17.
    Mechoulam R, Hanus LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 2014;15(11):757–64.Google Scholar
  18. 18.
    Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, International Union of Basic and Clinical Pharmacology. LXXIX, et al. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62(4):588–631.Google Scholar
  19. 19.
    Henstridge CM. Off-target cannabinoid effects mediated by GPR55. Pharmacology. 2012;89(3–4):179–87.Google Scholar
  20. 20.
    Henstridge CM, Balenga NA, Kargl J, Andradas C, Brown AJ, Irving A, et al. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol. 2011;25(11):1835–48.Google Scholar
  21. 21.
    Howlett AC. A short guide to the nomenclature of seven-transmembrane spanning receptors for lipid mediators. Life Sci. 2005;77(14):1522–30.Google Scholar
  22. 22.
    Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol. 2004;61(1):149–60.Google Scholar
  23. 23.
    Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol. 2001;63(5):569–611.Google Scholar
  24. 24.
    Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol. 2005;166(1–2):3–18.Google Scholar
  25. 25.
    Howlett AC. Cannabinoid receptor signaling. Handb Exp Pharmacol. 2005;168:53–79.Google Scholar
  26. 26.
    Ligresti A, Cascio MG, Di Marzo V. Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Disord. 2005;4(6):615–23.Google Scholar
  27. 27.
    Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(Suppl 1):S163–71.Google Scholar
  28. 28.
    Savage SR, Romero-Sandoval A, Schatman M, Wallace M, Fanciullo G, McCarberg B, et al. Cannabis in pain treatment: clinical and research considerations. J Pain. 2016;17(6):654–68.Google Scholar
  29. 29.
    Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(11 Suppl):11S–9S.Google Scholar
  30. 30.
    Gould J. The cannabis crop. Nature. 2015;525(7570):S2–3.Google Scholar
  31. 31.
    Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, et al. Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55(5):1209–17.Google Scholar
  32. 32.
    ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–9.Google Scholar
  33. 33.
    Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19.Google Scholar
  34. 34.
    Grof CPL. Cannabis, from plant to pill. Br J Clin Pharmacol. 2018;84(11):2463–7.Google Scholar
  35. 35.
    Romero-Sandoval EA, Fincham JE, Kolano AL, Sharpe BN, Alvarado-Vazquez PA. Cannabis for chronic pain: challenges and considerations. Pharmacotherapy. 2018;38(6):651–62.Google Scholar
  36. 36.
    Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of Cannabinoids. Br J Clin Pharmacol. 2018;Jul:12.Google Scholar
  37. 37.
    MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9.Google Scholar
  38. 38.
    Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791–802.Google Scholar
  39. 39.
    Starowicz K, Di Marzo V. Non-psychotropic analgesic drugs from the endocannabinoid system: “magic bullet” or “multiple-target” strategies? Eur J Pharmacol. 2013;716(1–3):41–53.Google Scholar
  40. 40.
    Kerbrat A, Ferre JC, Fillatre P, Ronziere T, Vannier S, Carsin-Nicol B, et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N Engl J Med. 2016;375(18):1717–25.Google Scholar
  41. 41.
    Lowin T, Straub RH. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res Ther. 2015;17:226.Google Scholar
  42. 42.
    Kaur R, Sidhu P, Singh S. What failed BIA 10-2474 phase I clinical trial? Global speculations and recommendations for future phase I trials. J Pharmacol Pharmacother. 2016;7(3):120–6.Google Scholar
  43. 43.
    Ahmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, et al. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. Eur Neuropsychopharmacol. 2014;24(9):1475–82.Google Scholar
  44. 44.
    Ahmed AI, van den Elsen GA, Colbers A, Kramers C, Burger DM, van der Marck MA, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology. 2015;232(14):2587–95.Google Scholar
  45. 45.
    Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571–84.Google Scholar
  46. 46.
    Hauser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547–64.Google Scholar
  47. 47.
    Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician. 2014;60(12):1083–90.Google Scholar
  48. 48.
    Allan GM, Ramji J, Perry D, Ton J, Beahm NP, Crisp N, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician. 2018;64(2):111–20.Google Scholar
  49. 49.
    Abuhasira R, Schleider LB, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018;49:44–50.Google Scholar
  50. 50.
    van den Elsen GA, Ahmed AI, Lammers M, Kramers C, Verkes RJ, van der Marck MA, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev. 2014;14:56–64.Google Scholar
  51. 51.
    National Academies of Sciences E, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017.Google Scholar
  52. 52.
    Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64(2):e78–94.Google Scholar
  53. 53.
    Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73.Google Scholar
  54. 54.
    Nugent SM, Morasco BJ, O’Neil ME, Freeman M, Low A, Kondo K, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017;167(5):319–31.Google Scholar
  55. 55.
    Mucke M, Phillips T, Radbruch L, Petzke F, Hauser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;7(3):CD012182.Google Scholar
  56. 56.
    Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;May:25.Google Scholar
  57. 57.
    Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan—European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–33.Google Scholar
  58. 58.
    Webb JA, LeBlanc TW. Evidence-based Management of cancer pain. Semin Oncol Nurs. 2018;34(3):215–26.Google Scholar
  59. 59.
    Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2013;22(7):CD003868.Google Scholar
  60. 60.
    Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39(2):167–79.Google Scholar
  61. 61.
    Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49.Google Scholar
  62. 62.
    Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19(4):23.Google Scholar
  63. 63.
    Gates P, Albertella L, Copeland J. Cannabis withdrawal and sleep: a systematic review of human studies. Subst Abus. 2016;37(1):255–69.Google Scholar
  64. 64.
    Rice J, Cameron M. Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep. 2018;18(8):50.Google Scholar
  65. 65.
    Yadav V, Narayanaswami P. Complementary and alternative medical therapies in multiple sclerosis—the American Academy of Neurology guidelines: a commentary. Clin Ther. 2014;36(12):1972–8.Google Scholar
  66. 66.
    Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep. 2018;18(2):8.Google Scholar
  67. 67.
    Stampanoni Bassi M, Sancesario A, Morace R, Centonze D, Iezzi E. Cannabinoids in Parkinson’s disease. Cannabis Cannabinoid Res. 2017;2(1):21–9.Google Scholar
  68. 68.
    Noel C. Evidence for the use of “medical marijuana” in psychiatric and neurologic disorders. Ment Health Clin. 2017;7(1):29–38.Google Scholar
  69. 69.
    Lim K, See YM, Lee J. A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci. 2017;15(4):301–12.Google Scholar
  70. 70.
    Shishko I, Oliveira R, Moore TA, Almeida K. A review of medical marijuana for the treatment of posttraumatic stress disorder: real symptom re-leaf or just high hopes? Ment Health Clin. 2018;8(2):86–94.Google Scholar
  71. 71.
    Mucke M, Weier M, Carter C, Copeland J, Degenhardt L, Cuhls H, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9(2):220–34.Google Scholar
  72. 72.
    Lavie-Ajayi M, Shvartzman P. Restored self: a phenomenological study of pain relief by cannabis. Pain Med. 2018;Sep:12.Google Scholar
  73. 73.
    Colizzi M, Bhattacharyya S. Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addict Rep. 2017;4(2):62–74.Google Scholar
  74. 74.
    Cohen K, Weinstein A. The effects of cannabinoids on executive functions: evidence from cannabis and synthetic cannabinoids—a systematic review. Brain Sci. 2018;8(3):10.Google Scholar
  75. 75.
    Choi NG, Marti CN, DiNitto DM, Choi BY. Older adults’ marijuana use, injuries, and emergency department visits. Am J Drug Alcohol Abuse. 2018;44(2):215–23.Google Scholar
  76. 76.
    Mensinga TT, de Vries I, Kruidenier M, Hunault CC, van den Hengel-Koot IS, Fijen JW, et al. A double-blind, randomized, placebocontrolled, cross-over study on the pharmacokinetics and effects of cannabis: Nationaal Vergiftigingen Informatie Centrum; 2006. Report no.: RIVM 267002002.Google Scholar
  77. 77.
    Beirness DJ, Beasley EE, Boase P. A comparison of drug use by fatally injured drivers and drivers at risk. In: Proceedings of the the 20th international conference on alcohol, drugs and traffic safety T-2013; Brisbane, Australia: International Council on Alcohol, Drugs, and Traffic Safety (ICADTS). 2013.Google Scholar
  78. 78.
    Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012;344:e536.Google Scholar
  79. 79.
    Singh A, Saluja S, Kumar A, Agrawal S, Thind M, Nanda S, et al. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 2018;7(1):45–59.Google Scholar
  80. 80.
    Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187–90.Google Scholar
  81. 81.
    Hackam DG. Cannabis and stroke: systematic appraisal of case reports. Stroke. 2015;46(3):852–6.Google Scholar
  82. 82.
    Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;371(9):879.Google Scholar
  83. 83.
    Desai R, Patel U, Sharma S, Amin P, Bhuva R, Patel MS, et al. Recreational marijuana use and acute myocardial infarction: insights from nationwide inpatient sample in the United States. Cureus. 2017;9(11):e1816.Google Scholar
  84. 84.
    Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28.Google Scholar
  85. 85.
    Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and mood disorders: a longitudinal study. J Affect Disord. 2015;1(172):211–8.Google Scholar
  86. 86.
    Ragazzi TCC, Shuhama R, Menezes PR, Del-Ben CM. Cannabis use as a risk factor for psychotic-like experiences: a systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. Early Interv Psychiatry. 2018;Jun:21.Google Scholar
  87. 87.
    Oh DJ, Park JY, Oh M, Kim K, Hong J, Kim T, et al. Suicidality-based prediction of suicide attempts in a community-dwelling elderly population: results from the Osan Mental Health Survey. J Affect Disord. 2015;15(184):286–92.Google Scholar
  88. 88.
    Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord. 2016;195:63–74.Google Scholar
  89. 89.
    Waterreus A, Di Prinzio P, Badcock JC, Martin-Iverson M, Jablensky A, Morgan VA. Is cannabis a risk factor for suicide attempts in men and women with psychotic illness? Psychopharmacology. 2018;May:16.Google Scholar
  90. 90.
    Nussbaum AM, Thurstone C, McGarry L, Walker B, Sabel AL. Use and diversion of medical marijuana among adults admitted to inpatient psychiatry. Am J Drug Alcohol Abuse. 2015;41(2):166–72.Google Scholar
  91. 91.
    Megale RZ, Deveza LA, Blyth FM, Naganathan V, Ferreira PH, McLachlan AJ, et al. Efficacy and safety of oral and transdermal opioid analgesics for musculoskeletal pain in older adults: a systematic review of randomized, placebo-controlled trials. J Pain. 2018;19(5): 475:e1–24.Google Scholar
  92. 92.
    Hauser W, Finnerup NB, Moore RA. Systematic reviews with meta-analysis on cannabis-based medicines for chronic pain: a methodological and political minefield. Pain. 2018;May:25.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Alan Edwards Pain Management UnitMcGill University Health CentreMontrealCanada
  2. 2.Department Internal Medicine IKlinikum SaarbrückenSaarbrückenGermany
  3. 3.Department of Psychosomatic Medicine and PsychotherapyTechnische Universität MünchenMunichGermany
  4. 4.Division of RheumatologyMcGill University Health CentreMontrealCanada
  5. 5.Montreal General HospitalMcGill University Health CentreMontrealCanada

Personalised recommendations